hotspot -WSS

hotspot

author：fashion 2025-09-05 11:32:46 - browse：97826

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Why CTE doesn’t keep Americans from enjoying the Super Bowl

explore

WSS

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Why Novartis is going to walk from its acquisition of MorphoSys

A protest over insulin prices is seen as a fight for life

Devoted Health’s losses in Medicare Advantage persist

Devoted Health’s losses in Medicare Advantage persist

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

explore

hotspot

focus

Activists slam private health insurers over coverage restrictions

A single Democrat is willing to weaken Medicare negotiation power

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In venture capital firm's success, lessons for turning crisis into profit

In Memoriam: Notable people who died in 2023

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Novavax promises a turnaround & Lilly roils the obesity market

Unique patient identifier: Experts argue the benefits, pitfalls

Sports medicine is finally prioritizing gender equality

Wegovy cuts risk of cardiovascular events by 20%, study finds

Wikipedia

Unique patient identifier: Experts argue the benefits, pitfalls

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Surgery pushed Ben Carson to fame

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Adopting new red light myopia treatments may be short

An Ebola outbreak presents a new mystery involving children

explore

hotspot

focus

focus